TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12829200
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with hydrocortisone (5 mg/d) and fludrocortisone (50 microg/d)
Study: 1771395
Drug: Ketoprofen, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen, 200 mg/day (50 mg q.i.d.) for 7 days
Study: 25180798
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate 20 mg
Study: 25159886
Drug: Active treatments
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatments (Lisdexamfetamine dimesylate and Armodafinil)
Study: 18541739
Drug: Single-tooth extraction
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-tooth extraction with amoxicillin prophylaxis
Study: 16003653
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (10 g/d x 10 d presurgery to 5 g/d x 30 d postsurgery)
Study: 10811324
Drug: Euglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia (blood glucose, 6 mmol/L)
Study: 10811324
Drug: Hyperglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (blood glucose, 15 mmol/L)
Study: 1800430
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (OC) with levonorgestrel (LNG) and norethisterone acetate (NEA)
Study: 1800430
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (OC) with levonorgestrel (LNG)
Study: 26603258
Drug: GSK2126458 (GSK458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2126458 (GSK458) at a maximum tolerated dose (MTD) of 2.5 mg once daily or twice daily dosing.
Study: 26603258
Drug: GSK2126458 (GSK458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2126458 (GSK458) at doses ranging from 0.1 to 3 mg once or twice daily.
Study: 26603258
Drug: GSK2126458 (GSK458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2126458 (GSK458) at a maximum tolerated dose (MTD) of 2.5 mg once daily.
Study: 22183158
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium 50 mg kg(‐1)
Study: 20382272
Drug: Transdermal drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal drug delivery system (TDDS) of Carvedilol (CRV)
Study: 20382272
Drug: Transdermal drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal drug delivery system (TDDS) of Hydrochlorothiazide (HCTZ)
Study: 20382272
Drug: Conventional immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immediate release oral tablets of Carvedilol (CRV)
Study: 20382272
Drug: Conventional immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immediate release oral tablets of Hydrochlorothiazide (HCTZ)
Study: 17284744
Drug: Daily supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplement containing folate (1 mg), vitamin B‐12 (500 microg), and vitamin B‐6 (10 mg)
Study: 16084158
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg 3 times daily
Study: 12047326
Drug: 3-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day triple therapy for H. pylori eradication
Study: 12047326
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy for H. pylori eradication
Study: 12047326
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori stool antigen before therapy
Study: 12047326
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori stool antigen after therapy
Study: 9989681
Drug: 1 MJ
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 MJ (340 mL) alcohol (wine or beer)
Study: 9989681
Drug: fat (cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: fat (cream fruit juice), protein (protein fruit juice), carbohydrate (grape juice)
Study: 8216442
Drug: Glimepiride (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (0.25 mg)
Study: 8216442
Drug: Glimepiride (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (0.50 mg)
Study: 8216442
Drug: Glimepiride (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1.25 mg)
Study: 8216442
Drug: Glimepiride (1.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1.50 mg)
Study: 3677789
Drug: Combination inhaler
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination inhaler therapy (salbutamol and beclomethasone dipropionate)
Study: 3677789
Drug: Separate inhaler
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate inhaler therapy (salbutamol and beclomethasone dipropionate)
Study: 24965573
Drug: Baricitinib (1-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (1-20 mg single ascending doses, 2-20 mg QD, 5 mg BID for 10 or 28 days)
Study: 19107071
Drug: N-acetyl-aspartyl glutamic
Normalized name: acetyl glutamic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-aspartyl glutamic acid (NAAGA) monotherapy over 4 weeks
Study: 19107071
Drug: Bi-therapy (NAAGA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-therapy (NAAGA and Levocabastine during the first week, then NAAGA only for the next 3 weeks)
Study: 11933906
Drug: Prime &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prime & Bond 2.1 (no D/Sense 2 treatment)
Study: 11933906
Drug: Bistite II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bistite II SC (no D/Sense 2 treatment)
Study: 12349021
Drug: Spermicidal preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spermicidal preparations containing nonoxynol-9 (gel products with varying amounts)
Study: 12349021
Drug: Suppository tablet
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository tablet and film preparation
Study: 8721468
Drug: i.m. ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. ketorolac (30 mg)
Study: 8721468
Drug: i.v. ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketorolac (30 mg)
Study: 8721468
Drug: intrawound (i.w.)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrawound (i.w.) ketorolac (30 mg)
Study: 8721468
Drug: p.o. ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o. ketorolac (30 mg)
Study: 1888644
Drug: Flupirtine 200
Normalized name: FLUPIRTINE
DrugBank: Flupirtine (DB06623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine 200 mg administered perorally
Study: 1888644
Drug: Flupirtine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine (various doses)
Study: 6356971
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg intramuscular buprenorphine
Study: 6356971
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intramuscular morphine
Study: 28842370
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone acetate (MP)
Study: 24907224
Drug: Simeprevir (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir (150 mg once daily, orally), peginterferon alfa 2a (180 μg once weekly, subcutaneous injection) or 2b (according to bodyweight), plus ribavirin (1000‐1200 mg/day or 800‐1400 mg/day, orally)
Study: 24907224
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily, orally), peginterferon alfa 2a or 2b, plus ribavirin
Study: 22925325
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus GG; ATCC 53103; 1 × 10(10) colony-forming units daily)
Study: 19757048
Drug: Balsalazide 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide 3 g/d (n = 38)
Study: 19757048
Drug: Balsalazide 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide 3 g/d
Study: 11435055
Drug: Continuous modified
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous modified glucose-insulin-potassium infusion
Study: 11435055
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous (IV) insulin injections
Study: 9526936
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (300 microg)
Study: 9526936
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) clonidine (300 microg)
Study: 464807
Drug: Doxycycline hyclate
Normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline hyclate 100 mg twice daily on postoperative days 5 through 10 and then 100 mg daily for six weeks
Study: 27914210
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) using egg
Study: 22201659
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention started at the beginning of chemotherapy (EE)
Study: 22201659
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention started at the completion of chemotherapy (CE)
Study: 19502623
Drug: Warfarin use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin use in patients with AF at discharge
Study: 19502623
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation therapy at discharge
Study: 19502623
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy among patients with coronary stents
Study: 19502623
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation in patients at highest risk of stroke (CHADS(2) score >=2)
Study: 9673431
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 or 5 mg once daily)
Study: 3293372
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus (150 ml or 175 ml depending on weight)
Study: 3293372
Drug: Split bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split bolus (first bolus 100 or 125 ml, second bolus 50 ml)
Study: 3293372
Drug: Bolus-drip (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus-drip (initial bolus 100 or 125 ml followed by rapid IV drip infusion of 50 ml)
Study: 30260268
Drug: Zolpidem 5
Normalized name: zolpidem 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 5 mg for 7 days
Study: 26289557
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional anti-HF therapies)
Study: 21843876
Drug: argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: argon laser trabeculoplasty (ALT) after topical betaxolol hydrochloride treatment
Study: 11182175
Drug: Telmisartan 10
Normalized name: telmisartan 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 10 mg once daily
Study: 11182175
Drug: Telmisartan 20
Normalized name: telmisartan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 20 mg once daily
Study: 9156375
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution (45 micrograms nicotine base/kg)
Study: 9156375
Drug: Intravenous nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nicotine (15 micrograms nicotine base/kg)
Study: 25145781
Drug: Tacrolimus +
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus + Wuzhi capsules (WZC) + corticosteroids
Study: 22205241
Drug: 800 MBq
Normalized name: dotatate
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 MBq I‐131 (low dose)
Study: 22205241
Drug: 3700 MBq
Normalized name: dotatate
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3700 MBq I‐131 (high dose)
Study: 21147441
Drug: Ajmaline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ajmaline (1 mg/kg) infused at 1 mg/sec
Study: 21147441
Drug: Ajmaline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ajmaline (1 mg/kg) infused over 10 minutes
Study: 21147441
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion rate (assessed retrospectively during 386 challenges)
Study: 21147441
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion rate (assessed during the study)
Study: 21147441
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion rate (assessed during the study)
Study: 18056188
Drug: High-dose glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucocorticoid therapy
Study: 16265847
Drug: Continuous axillary
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous axillary brachial plexus block with 10 ml 0.75% ropivacaine loading dose followed by 4-5 ml per hour infusion for up to three days (Group A)
Study: 12410195
Drug: 1% Permethrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Permethrin Creme Rinse (1% PLT) with adjunctive combing
Study: 9857653
Drug: Bronchoalveolar lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchoalveolar lavage (BAL) mast cell analysis using Carnoy's solution as a fixative and 0.5% solution of Toluidine blue for staining.
Study: 27539
Drug: Clobazam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (30 to 40 mg/day in three divided doses)
Study: 27539
Drug: Diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (15 to 20 mg/day in three divided doses)
Study: 31883327
Drug: Fosfomycin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (4 g dose intravenously 3 hours before catheter placement and removal)
Study: 30728754
Drug: Location of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Location of hormone replacement therapy
Study: 16678550
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg for 2 days, then two 50 mg doses 12 hours apart for 5 days)
Study: 11786648
Drug: DAG (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAG (20 g daily for 12 weeks)
Study: 11786648
Drug: TAG (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAG (20 g daily for 12 weeks)
Study: 8133022
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg amlodipine taken in the morning
Study: 8133022
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg amlodipine taken in the evening
Study: 8133022
Drug: Medication-Event-Monitoring System
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication-Event-Monitoring System (MEMS)
Study: 8133022
Drug: Days with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days with missed medication removed from analysis
Study: 3499896
Drug: Antimotion sickness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimotion sickness medications scopolamine:d‐amphetamine (0.4:5.0 mg)
Study: 3499896
Drug: Promethazine:ephedrine (25:60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine:ephedrine (25:60 mg)
Study: 3499896
Drug: Naproxyn (275
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxyn (275 or 550 mg)
Study: 30950739
Drug: Short-term intensive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term intensive voice therapy (IVT)
Study: 30950739
Drug: Group IVT
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group IVT (IVT-G)
Study: 30950739
Drug: Long-term traditional
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term traditional voice therapy (TVT)
Study: 26672793
Drug: Integrated intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated intervention (cognitive behavioural therapy)
Study: 24508419
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg) at a fixed dose level of 0.6 U/kg for 6 days
Study: 24508419
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir at a fixed dose level of 0.6 U/kg for 6 days
Study: 14655848
Drug: Combined Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Group Psychoeducation and Fluoxetine (GPF)
Study: 7951808
Drug: Homemade cereal‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homemade cereal‐based oral rehydration therapy (HC‐ORT, n = 103)
Study: 7951808
Drug: Glucose‐based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose‐based oral rehydration solution (G‐ORS, n = 98)
Study: 7951808
Drug: Cereal‐based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal‐based oral rehydration solution (C‐ORS, n = 90)
Study: 3311117
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg salbutamol
Study: 3311117
Drug: 1.6 mg
Normalized name: menthol 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg salbutamol
Study: 3311117
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg salbutamol
Study: 21682757
Drug: LB03002 (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB03002 (sustained-release recombinant growth hormone) for 12 months
Study: 21682757
Drug: LB03002 (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB03002 (sustained-release recombinant growth hormone)
Study: 20172051
Drug: CeO(2) nanoparticles;
Approvals — FDA: no, EMA: no, PMDA: no
Description: CeO(2) nanoparticles; intraperitoneal injections before radiation exposure.
Study: 18343738
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy combined with probiotics
Study: 18343738
Drug: Alternative therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative therapeutic options (immunotherapy, ion-exchange resins, new drugs)
Study: 16319952
Drug: Carmustine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carmustine (300 mg/m2) + Melphalan (200 mg/m2)
Study: 11052393
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored sensory and coping information about analgesic side effects
Study: 11127439
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor treatment started 3.2 ± 1.7 hours after MI
Study: 1575341
Drug: 26-G needle
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 26-G needle
Study: 1575341
Drug: 27-G needle
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 27-G needle
Study: 23689708
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (ZnSO4) 125 mg daily for 14 days
Study: 10893655
Drug: Solid paracetamol
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid paracetamol
Study: 1333637
Drug: heparin 5000
Normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin 5000 IU and dihydroergotamine 0.5 mg 8 h‐1
Study: 1333637
Drug: dextran 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextran 500 ml 12 h‐1 on the day of surgery and 500 ml on days 1, 3, and 5 postoperatively
Study: 6368776
Drug: Intermittent lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent lipid infusion (8 hours/day)
Study: 6368776
Drug: Continuous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous lipid infusion (24 hours/day)
Study: 28742409
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU vitamin D3 plus 1000 mg evening primrose oil (EPO)
Study: 24952576
Drug: Concentrated Triglyceride
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated Triglyceride (rTG) fish oil: EPA of 650 mg, DHA of 450 mg
Study: 24952576
Drug: Ethyl Ester
Normalized name: Amben ethyl ester
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethyl Ester (EE) fish oil: EPA of 756 mg, DHA of 228 mg
Study: 24952576
Drug: Triglyceride (TG)
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride (TG) salmon oil: EPA of 180 mg, DHA of 220 mg
Study: 24952576
Drug: Phospholipid (PL)
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phospholipid (PL) krill oil: EPA of 150 mg, DHA of 90 mg
Study: 16158737
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment including complex physical factors (CAP‐ELM‐01)
Study: 14703267
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment models for homeless individuals with severe mental illness; details on dosage and duration not available.
Study: 1948658
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg intravenous methylprednisolone before ECMO
Study: 30918434
Drug: Khubchandani's procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Khubchandani's procedure with stapled posterior rectal wall resection (group A)
Study: 28742515
Drug: Paracetamol as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol as adjunct analgesia